| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Alcon develops, manufactures and markets pharmaceuticals, surgical equipment
and devices, and consumer products to treat diseases and disorders of the eye.
This new strategic analysis report provides a complete and critical review of
the company and includes unique and independent assessments and forecasts of
key products.
Alcon is a research and development-driven global company which develops,
manufactures and markets pharmaceuticals, surgical equipment and devices, and
consumer products to treat diseases and disorders of the eye. A subsidiary of
Nestlé, Alcon is a Swiss corporation with operations in over 75
countries. Its products are sold in more than 180 countries.
Alcon's corporate strategy is to attempt to offer the broadest and most
advanced product line in the industry, developing market share of core brands
and seeking global registrations of products to fully utilise its network of
75 international subsidiaries. In 2006, Alcon obtained more than 500 new
product approvals worldwide, including more than 70 in the key markets of the
US, Canada, the EU, Japan and Australia.
Since Alcon's initial public offering in 2002, its sales and income have shown
steady growth as it continues to maintain a leadership position in the eye
care industry. The company is continuing its investment in: research and
development programmes to advance its pipeline of potential new products;
manufacturing; and marketing support.
Sales growth was seen in all pharmaceutical categories in 2006, and in the
short term this looks set to continue. However, as patent expiries begin to
affect the sales of a number of Alcon's major products, the company will face
an increasingly challenging environment as it seeks to advance development
products to market. In addition, Alcon faces significant competition in
ophthalmic pharmaceuticals, including competition from other companies with an
ophthalmic focus and from larger pharmaceutical companies. The successful
approval of Alcon's major late-stage development product, Retaane, will be
crucial, along with the population of the pipeline with further new projects.
This new strategic analysis report Alcon: Performance, Products, Pipeline and
Potential, provides a complete and critical review of the company and includes
unique and independent assessments and forecasts of key products. The report
is updated on a quarterly basis. Buyers of the web edition receive quarterly
reports for a year. Buyers of the print/pdf editions receive the latest
version. All formats are the same price.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Segment Performance
- Company Strategy
- Product Performance Forecasts
- Pipeline Analysis
- Other Factors Affecting the Bottom Line
- Conclusions/Outlook
THERAPEUTIC AREA FOC US
R&D PIPELINE
OPHTHALMOLOGY
- Marketed Products
- Glaucoma
- Anti-infective/Anti-inflammatory
- Nevanac
- Rimexel
- TobraDex
- Vigamox/Vegamox
- Ocular Allergy
- Other
- R&D Projects
- Growth Forecast
OTIC
- Marketed Products
- R&D Projects
- Growth Forecast
APPENDIX 1 - FINANC IAL PERFORMANC E
APPENDIX 2 - KEY CO RPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- Amgen
- Dharmacon Inc
- Eli Lilly
- Jerini AG
- Juvantia Pharma Ltd
- Kalypsys Inc
- Kyowa Hakko
- NovaCal Pharmaceuticals Inc
- Vernalis plc
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMAC EUTICAL
- SUBSIDIARIES
- Subsidiaries
APPENDIX 6 - PRODUCT INDEX
Index of Tables
- Principal Operating Results
- Sales By Business/Geographic Segment
- Operating Income By Segment
- Sales By Product Area
- Recent Product Approvals
- Major Therapeutic Areas And Sales
- Major Glaucoma Products, 2006
- Major Anti-infective/ Anti-inflammatory Products, 2006
- Major Ocular Allergy Products, 2006
Index of Charts
- Sales By Segment, 2006
- Sales By Product Area, 2006
- Glaucoma Sales (2004A-2011E)
- Anti-infect/Anti-inflammatory Sales (2004A-2011E)
- Ocular Allergy Sales (2004A-2011E)
- Otic Sales (2004A-2011E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
